Core Viewpoint - Shineco Inc. has entered into a partnership with Plus Me Limited to create a blockchain-based tokenization system for biological cellular assets, aiming to transform the global biological cell industry and enhance the commercial architecture of cell therapy [1][5][6] Group 1: Partnership and Agreement - The partnership involves a "Cellular Asset On-Chaining and Marketing Ecosystem Cooperation Agreement" that facilitates the tokenization of Shineco's mesenchymal stem cells (MSCs) on the Ethereum blockchain [1][2] - Plus Me will provide full lifecycle digital custody of the MSCs, ensuring asset ownership rights through smart contracts and issuing unique non-fungible digital identifiers (NFDIs) for traceability [2][3] Group 2: Tokenization Framework - Plus Me will issue ERC-1400/ERC-20 compliant security tokens named "Cell Infusion Redemption Tokens," which can be redeemed at Shineco-affiliated Cell Therapy Centers [3] - The tokenization framework aims to address industry challenges such as high user costs and unverifiable product provenance, converting biological assets into tradable digital instruments [3] Group 3: Strategic Acquisitions - Shineco has acquired a controlling 51% stake in Xi'an Dong'ao Health Management Co., Ltd., enhancing its off-chain infrastructure for token redemption [4] - This acquisition, along with the previously acquired Singapore firm Infiniclone, allows Shineco to establish a global storage and infusion network for on-chain and off-chain asset settlement [4] Group 4: Ecosystem Development - The collaboration will create an open-cell industry ecosystem where Plus Me provides tokenization SaaS to third parties, while Shineco offers its physical custody network [5] - Shineco's initiative positions the company as a global infrastructure provider for the cell economy, enabling rapid revenue scalability [5][6] Group 5: Industry Transformation - Shineco's asset tokenization protocol aligns with the industry's shift towards commercial scalability, marking the emergence of a decentralized biotech economy [6] - Token holders will gain governance rights, including future DAO voting, which will enhance the development of the global ecosystem in cell therapy [6]